Divestments

Divestments are an important part of any corporate company's growth strategy and require the same skill of execution — and dedication to the process — as any other transaction. With a strong track record in company divestitures, undertaken for a multitude of international corporates, we can help you realign your portfolio and redeploy capital to the growth of your core business.

With our experienced team, sector insights and buyer access, we can deliver a transaction at the optimal deal terms and structure.

Divestments Deals

Jul 2022
has divested its API site in Rhode Island, USA, to
May 2021
has formed a strategic alliance with
Jan 2021
has divested its Mirabel manufacturing site in Riom, France to
Jan 2021
has divested its Ringaskiddy analytics and testing site to
Nov 2020
has been acquired by
a division of Constellation Software
Oct 2020
a Calculus Capital-backed company
has divested its mainframe RPA and terminal-emulation products to
a Bain Capital-backed company
Oct 2020
has divested its Poznań, Poland manufacturing site to
Sep 2020
has divested its Barcelona manufacturing sites to
Sep 2020
has divested its Segré, France manufacturing facility to
Jun 2020
has been acquired by
A company backed by TA Associates, HGGC, Charlesbank, Harvest Partners SCF

CG Results. Great people creating great outcomes, together.

Latest Insights

Reports
23rd November 2022

Pharma Licensing – an introduction

We are pleased to share our introduction to Pharma Licensing. This guide provides an overview of both in and out-licensing as well as insights on what to anticipate during the process. We hope that you find this guide useful and look forward to discussing the underlying themes with you. Do get in touch! Click to […]

Insights
17th October 2022

Pharma Licensing: the why the how and a few things to get right

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]

Reports
17th October 2022

MedTech Services – Drivers of growth and consolidation

Welcome to our MedTech Services Report. This sets out our views on the tailwinds driving growth and increased outsourcing, an overview of the MedTech CDMO and CRO market as well as the key drivers of consolidation in the sector. We hope that you enjoy this report and look forward to discussing the data and underlying […]